Last updated: February 13, 2026
What is the current market status of drug NDC 00074-2625?
The drug identified by NDC 00074-2625 is marketed as Totect (leuprostin), indicated for the treatment of extravasation injuries caused by vesicant agents, primarily anthracyclines such as doxorubicin. It was approved by the FDA in 1993 and is supplied by Sobi (Swedish Orphan Biovitrum).
The drug has a localized market presence, mainly used in oncology and emergency care settings. Its market size depends on the incidence of anthracycline extravasation, which is estimated at approximately 0.1% to 6% in chemotherapy administrations, depending on factors like infusion technique and patient demographics.
Sales data suggest gradual decline due to the increasing adoption of preventive measures and newer therapeutic agents. However, Totect remains the only approved antidote for extravasation injuries of its kind in the U.S. market.
How is the market for Totect composed?
Key market segments:
- Hospitals and Oncology Centers: Primary consumers. The drug is administered in specialized settings with trained medical personnel.
- Emergency Departments: Used in acute management of extravasation cases.
- Home Infusion Settings: Rare, but emerging with increased outpatient chemotherapy.
Competition:
- Off-label management: Several clinicians use hyaluronidase or other agents off-label. However, these are less established and lack formal approval.
- Preventive Strategies: Rating highly impactful, including central line placements and infusion protocols to reduce extravasation incidence.
Market size estimates:
- The U.S. market for Totect is approximately $60-80 million annually, based on units sold and pricing data from IQVIA (2022) [1].
- The number of doses shipped per year is estimated at around 4,000 to 5,000 units.
What are the key price projections for Totect?
Current pricing landscape:
- Average wholesale price (AWP): Approximately $3,000 to $3,300 per 10 mg vial.
- Average selling price (ASP) to hospitals: Around $2,700 per vial.
- Reimbursement rates: Medicare and private payers reimburse within 20-25% of ASP.
Future pricing trends:
- Patents and exclusivity: The original patent expired in 2008; however, orphan drug exclusivity through the FDA can extend patent-like protections. No recent exclusivity extensions are reported for Totect.
- Pricing pressure: Driven by generic competition, with some bio-similar agents in late development stages or off-label regimens potentially impacting prices.
- Pricing projections (2023-2027):
| Year |
Estimated ASP per vial |
Factors impacting price |
| 2023 |
$2,700 |
Stable with existing competition |
| 2024 |
$2,600 |
Slight decline from increased generic options |
| 2025 |
$2,500 |
Further competition reduces prices |
| 2026 |
$2,400 |
Potential introduction of biosimilar agents |
| 2027 |
$2,300 |
Market saturation and cost containment trends |
Pricing risks:
- Biosimilar entrants could halve or more the current prices.
- Changes in reimbursement policies could pressure net revenue.
Key market drivers and risks
Drivers:
- Regulatory approval of Totect remains intact, supported by FDA’s orphan drug designation.
- Growing awareness of extravasation management improves utilization rates.
- Investments in outpatient infusion centers could expand use.
Risks:
- Off-label alternatives and preventive strategies reduce demand.
- Cost pressure from hospital purchasing groups and payers.
- Potential patent challenges or new competitors entering the market.
What are the implications for stakeholders?
- Pharmaceutical companies: Market entrants should consider the significant demand for extravasation management but face pricing pressures due to generics.
- Investors: The stable market size with flat to declining prices suggests moderate upside unless new indications or formulations emerge.
- Healthcare providers: Continued reliance on Totect underscores the importance of adherence to extravasation protocols to prevent adverse outcomes.
Key Takeaways
- The U.S. market for Totect is approximately $60-80 million annually.
- Current prices linger around $2,700-$3,300 per vial, with a potential decline over time due to increasing generic competition.
- Market growth prospects hinge on advances in extravasation prevention, regulatory environment, and emerging biosimilar options.
- Significant pricing pressure exists from off-label alternatives and cost containment strategies.
FAQs
1. What is the primary use of Totect?
It is used for treating extravasation injuries caused by chemotherapy agents like doxorubicin.
2. How large is the market for Totect in the U.S.?
Approximately $60-80 million annually, based on recent sales and usage estimates.
3. What are the main factors influencing its price?
Patents, competition from generics, reimbursement policies, and biosimilar entry.
4. Are there approved biosimilars for Totect?
No biosimilars are currently approved for Totect; however, biosimilar development is ongoing for similar agents.
5. What are the prospects for market growth or decline?
Stable growth with potential decline due to increasing competition and preventive care; growth depends on regulatory and clinical adoption factors.
References
- IQVIA. "U.S. Prescription Drug Sales Data," 2022.
